LNSR Stock Analysis: Buy, Sell, or Hold?
LNSR - LENSAR, Inc. Common Stock
$8.30
-0.16 (-1.89%)
▼
5d:
-4.38%
30d:
+60.54%
90d:
+43.1%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When LNSR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LNSR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LNSR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LNSR is currently trading at $8.30, which is considered extended relative to its 30-day fair value range of $5.35 to $8.24. From a valuation perspective, the stock is trading at a discount (Forward PE: -11.7) compared to its historical average (14.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LNSR is in a uptrend. Immediate support is located at $7.99, while resistance sits at $9.25.
Market Sentiment: LNSR scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+38.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LNSR is in a uptrend. Immediate support is located at $7.99, while resistance sits at $9.25.
Market Sentiment: LNSR scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+38.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.35 -
$8.24
Company Quality Score
36/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: Trading 38.6% below Wall St target ($11.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.35 -
$8.24
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.99
Resistance Level
$9.25
Current Trend
Uptrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.69
Wall Street Target
$11.50
(+38.6%)
Revenue Growth (YoY)
18.4%
Profit Margin
57.6%
PE vs Historical
-11.7 vs 14.6
CHEAP
Share & Embed Analysis
Last updated: August 28, 2026 5:29 PM ET
Data refreshes hourly during market hours. Next update: 6:29 PM
Data refreshes hourly during market hours. Next update: 6:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LNSR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 43 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 49 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 43 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 53 HOLD |
